The EUnetHTA 21 2nd Open Call for applications from the pharmaceutical industry for Joint Scientific Consultations (JSCs) closed on 31 August, 2022.
The EUnetHTA 21 Committee for Scientific Consistency and Quality (CSCQ) JSC reviewed the applications received and selected five additional JSCs to be conducted within the framework of EUnetHTA 21.
These five JSCs will be consultations on medicinal products in parallel to EMA scientific advice, starting end of October 2022. Amongst the selected JSCs there are three oncological and two non-oncological products: 5x First in class (FC), 2x Orphan designation (OD), 2x ATMP, 1x PRIME and 1x SME.
More information can be found here:
